Home › Idiopathic Thrombocytopenic Purpura › North Carolina
Pag-aaral pangklinika para sa Idiopathic Thrombocytopenic Purpura sa North Carolina
7 pag-aaral para sa Idiopathic Thrombocytopenic Purpura ang naghahanap ng mga kalahok sa mga site sa North Carolina.
Mga Lungsod sa North Carolina
Opisyal na teksto ng pag-aaral (English)
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Duke University Hospital, Durham
- East Carolina University, Greenville
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 18, 2026 · NCT06722235Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia
- East Carolina University, Greenville
Nagre-recruitPhase 2
Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Set 14, 2026 · NCT07095127A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)
- East Carolina University, Greenville
Nagre-recruitPhase 3
Edad 18 hanggang 70 · Lahat ng kasarian · Na-update Set 11, 2026 · NCT07059000A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Duke University Hospital, Durham
- East Carolina University, Greenville
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT06948318Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
- Universtity of North Carolina at Chapel Hill, Chapel Hill
Nagre-recruitPhase 1
Edad 18 hanggang 85 · Lahat ng kasarian · Na-update Hul 22, 2026 · NCT06371417Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
- East Carolina University, Greenville
Nagre-recruitPhase 2
Edad 18 hanggang 70 · Lahat ng kasarian · Na-update May 12, 2026 · NCT05070845A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
- Duke University Medical Center, Durham
- Brody School of Medicine at East Carolina University, Greenville
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update May 1, 2026 · NCT06544499Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.